Vertex Corrects Earlier Interim Data
Posted on May 30, 2012 at 16:47 PM EDT
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) recently corrected previously reported interim data (responder analysis) from a phase II study of VX-809 and Kalydeco. Vertex also provided some additional data from the study. The interim data from the phase II study showed improvements in lung function in adults with cystic fibrosis (CF) who had two copies of the [...]
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) recently corrected previously reported interim data (responder analysis) from a phase II study of VX-809 and Kalydeco. Vertex also provided some additional data from the study.
NASDAQ Gainers Watch List: Alkermes plc (NASDAQ:ALKS), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), and Pharmacyclics Inc. (NASDAQ:PCYC) Added to Equity Profile Report's NASDAQ Gainers Watch Lis
May 21, 2013
Earnings Look Back: Vertex Pharmaceuticals Is Up 3.5% Since Reporting Quarterly Results 2 Weeks Ago (VRTX)
May 20, 2013
from Forbes Real Time
Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015
May 17, 2013
MDY, VRTX, KSU, AME: Large Inflows Detected at ETF
May 16, 2013
from ETF Channel
(MRK) Merck & Company Joins Forces With Bristol-Myers Squibb on Hepatitis C Virus Candidates
May 14, 2013
from Stock Blog Hub
Short Interest in Vertex Rises, in Celgene Falls
May 11, 2013
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here